HC Wainwright Has Positive Outlook for JSPR FY2025 Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Research analysts at HC Wainwright upped their FY2025 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a report issued on Monday, November 10th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($4.62) per share for the year, up from their previous estimate of ($5.96). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q4 2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.82) EPS, Q4 2026 earnings at ($0.95) EPS, FY2026 earnings at ($3.29) EPS, FY2027 earnings at ($1.31) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.86) EPS.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Monday, November 10th. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.12).

JSPR has been the subject of a number of other reports. Evercore ISI reduced their price objective on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a research note on Monday, September 22nd. JMP Securities cut their price objective on Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a research report on Monday, September 22nd. UBS Group dropped their price target on Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Friday, August 15th. BTIG Research reduced their price objective on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $25.63.

Jasper Therapeutics Price Performance

Shares of NASDAQ:JSPR opened at $1.70 on Wednesday. The stock has a market capitalization of $27.63 million, a P/E ratio of -0.29 and a beta of 2.83. The business has a 50-day moving average of $2.37 and a two-hundred day moving average of $3.62. Jasper Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $26.05.

Insider Activity

In related news, Director Svetlana Lucas acquired 20,000 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was purchased at an average price of $2.43 per share, for a total transaction of $48,600.00. Following the transaction, the director directly owned 20,000 shares of the company’s stock, valued at approximately $48,600. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Thomas G. Wiggans acquired 41,000 shares of Jasper Therapeutics stock in a transaction on Monday, September 22nd. The shares were purchased at an average cost of $2.43 per share, for a total transaction of $99,630.00. Following the acquisition, the director owned 41,000 shares in the company, valued at approximately $99,630. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 143,000 shares of company stock worth $347,490. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Jasper Therapeutics

Several large investors have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new stake in Jasper Therapeutics in the first quarter worth about $46,000. Marex Group plc acquired a new position in Jasper Therapeutics during the 2nd quarter valued at about $74,000. Engineers Gate Manager LP bought a new position in shares of Jasper Therapeutics in the 2nd quarter valued at about $78,000. Corton Capital Inc. bought a new position in shares of Jasper Therapeutics in the 1st quarter valued at about $113,000. Finally, XTX Topco Ltd bought a new stake in shares of Jasper Therapeutics during the second quarter worth approximately $152,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.